Laghrissi-Thode Fouzia 4

What Happened
Fouzia Laghrissi‑Thode, a non-employee director of Minerva Neurosciences, was granted a 50,000-share derivative award (reported as an acquisition at $0) on June 3, 2026. The filing lists the acquisition price as $0, so the immediate reported value is $0; the award is described in the filing as an option-like award that vests over time rather than an open-market purchase.

Key Details

• Transaction date: June 3, 2026; Form 4 filed June 5, 2026 (Accession: 0001642015-26-000002).
• Amount: 50,000 shares reported as a derivative award; reported acquisition price $0 (total $0 shown on form).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The award vests in four equal quarterly installments (1/4 every three months), with the first 1/4 vesting three months after June 3, 2026 (i.e., Sept 3, 2026), subject to continued service as a non-employee director.
• Timeliness: Filing was submitted two days after the transaction date and appears to meet the usual two-business-day Form 4 timing requirement.

Context
This is a compensatory equity award (derivative/option-type grant) to a director and not an open-market purchase or sale. Such awards are common for director compensation and vest over time, so they do not necessarily signal immediate buying or selling intent. There was no immediate exercise or sale reported in this filing.